Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Hypercholesterolemia Therapeutics – Pipeline Assessment and Market Forecasts to 2017Hypercholesterolemia Therapeutics Market is Forecast to Show Moderate Growth
By: Rajesh Gunnam (Niacin) in 2013, Pravachol (pravastatin) GlobalData’s pipeline analysis revealed that there are 22 candidates in various stages of clinical development for the hypercholesteromia therapeutics sector. The late stage of the pipeline, which consists of filed products and Phase III trials, has nine pipeline molecules, one of which, Pitavastatin, is filed for approval in Europe. There are six molecules in Phase II, Phase I consists of two molecules, and five molecules are in the pre-clinical and discovery phases. The pipeline consists of many novel therapies such as MK-0524A and MK-0524B by Merck & Co., Inc., AEGR-733 by Aegerion Pharmaceuticals, Inc. and ISIS301012 by Genzyme Corporation, which are expected to be promising candidates for the hypercholesterolemia therapeutics market. The pipeline molecules differ from each other in terms of their mechanisms of action, and could capture significant portions of the current market on approval. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ There are many therapies in the market to treat hypercholesterolemia by reducing blood low-density lipoprotein (LDL) and total cholesterol (TC) level. Statins, nicotinic acid and fenofibrates are mostly prescribed by medical practitioners to treat hypercholesterolemia. The unmet need for the hypercholesterolemia therapeutics market was estimated to be approximately $4 billion. Currently, there are significant patient populations that are likely to switch over to new products with better efficacy and safety and the therapeutics pipeline contains many novel therapies with potentially better efficacy and safety profile which, if approved, will capture the market. GlobalData, the industry analysis specialist, has released its new report, “Hypercholesterolemia Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global hypercholesterolemia market. The report identifies the key trends shaping and driving the global hypercholesterolemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hypercholesterolemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number